Egetis Therapeutics
Develops and commercializes treatments for serious and rare diseases.
EGTX | ST
Overview
Corporate Details
- ISIN(s):
- SE0003815604
- LEI:
- 549300RZCKGWRUBPMY22
- Country:
- Sweden
- Address:
- Klara Norra Kyrkogata 26, 111 22 Stockholm
- Website:
- https://www.egetis.com/
- Sector:
- Manufacturing
Description
Egetis Therapeutics is an innovative and integrated pharmaceutical company focused on developing and commercializing treatments for serious and rare diseases with significant unmet medical needs. The company's strategy centers on advancing drug candidates through late-stage clinical development to market approval. Its primary asset, Emcitate (tiratricol), is a first-in-class drug candidate in late-stage development for the treatment of Monocarboxylate Transporter 8 (MCT8) deficiency, a rare congenital disorder of thyroid hormone transport.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-02-17 08:00 | English | 400.1 KB | |||
| 2021-02-15 08:30 |
Egetis Therapeutics utser Dr Kristina Sjöblom Nygren till ny CMO
|
Swedish | 71.3 KB | ||
| 2021-02-15 08:30 |
Egetis appoints Dr Kristina Sjöblom Nygren as new CMO
|
English | 73.4 KB | ||
| 2021-01-20 15:00 |
Peder Walberg appointed as interim Chief Medical Officer
|
English | 77.0 KB | ||
| 2021-01-20 15:00 |
Peder Walberg utsedd till interim Chief Medical Officer
|
Swedish | 81.3 KB | ||
| 2020-12-30 15:48 | English | 33.9 KB | |||
| 2020-12-30 15:30 |
Change in the number of shares and votes in Egetis Therapeutics
|
English | 93.3 KB | ||
| 2020-12-30 15:30 |
Ändring av antalet aktier och röster i Egetis Therapeutics
|
Swedish | 95.9 KB | ||
| 2020-12-22 16:00 |
Nomination Committee appointed for the 2021 Annual General Meeting in Egetis Th…
|
English | 79.5 KB | ||
| 2020-12-22 16:00 |
Valberedning utsedd inför årsstämman 2021 i Egetis Therapeutics
|
Swedish | 102.2 KB | ||
| 2020-12-17 15:00 |
PledPharma changes its name to Egetis Therapeutics with focus on late stage orp…
|
English | 97.0 KB | ||
| 2020-12-17 15:00 |
PledPharma blir Egetis Therapeutics med fokus på utveckling av särläkemedel i s…
|
Swedish | 102.4 KB | ||
| 2020-12-15 08:00 |
Results from the prematurely closed PledOx POLAR program
|
English | 165.1 KB | ||
| 2020-12-15 08:00 |
Resultat från det i förtid avslutade POLAR programmet med PledOx
|
Swedish | 166.4 KB | ||
| 2020-12-11 14:30 |
Kommuniké från extra bolagsstämma i PledPharma AB (publ) den 11 december 2020
|
Swedish | 118.4 KB |
Automate Your Workflow. Get a real-time feed of all Egetis Therapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Egetis Therapeutics
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Egetis Therapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-09 | Yilmaz Mahshid | Other | Sell | 39,753 | 268,332.75 SEK |
| 2025-01-08 | Yilmaz Mahshid | Other | Sell | 98,567 | 653,499.21 SEK |
| 2025-01-07 | Yilmaz Mahshid | Other | Sell | 74,769 | 507,681.51 SEK |
| 2024-10-07 | Nicklas Westerholm | Other | Buy | 10,142 | 43,103.50 SEK |
| 2024-10-07 | Yilmaz Mahshid | Other | Buy | 10,000 | 42,250.00 SEK |
| 2023-07-07 | Henrik Krook | Other | Buy | 33,594 | 133,704.12 SEK |
| 2023-07-06 | Christian Sonesson | Other | Buy | 3,616 | 14,391.68 SEK |
| 2023-07-06 | Christian Sonesson | Other | Buy | 2,000 | 7,920.00 SEK |
| 2023-07-05 | Christian Sonesson | Other | Buy | 1,384 | 5,452.96 SEK |
| 2023-07-04 | Nicklas Westerholm | Other | Buy | 15,350 | 60,632.50 SEK |
Peer Companies
